Prosecution Insights
Last updated: August 15, 2026
Application No. 17/298,321

NOVEL TUMOR ANTIGEN BINDING AGENTS AND USES THEREOF

Non-Final OA §112
Filed
May 28, 2021
Priority
Nov 28, 2018 — EU PCT/EP2018/082910 +1 more
Examiner
DICKINSON, PAUL W
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Paul Scherrer Institut
OA Round
3 (Non-Final)
63%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
73%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
653 granted / 1039 resolved
+2.8% vs TC avg
Moderate +10% lift
Without
With
+9.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
40 currently pending
Career history
1079
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
42.3%
+2.3% vs TC avg
§102
17.8%
-22.2% vs TC avg
§112
26.9%
-13.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1039 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6/26/2026 has been entered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objects are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 40-44 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claims recite “as defined above.” It’s unclear what the antecedent basis is for “as defined above,” as the claim does not specify a specific claim or portion of a specific claim that it is referring to nor what it means to be “as defined above.” Allowed Claims The Declaration under 37 CFR 1.130(a) filed 1/17/2026 is sufficient to overcome the prior art rejection of claims 8-39 and 45-59 based upon Umbricht (Pharmaceutics, 2018). No prior art against the invention was found. Claims 8-39 and 45-59 are allowed. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL W DICKINSON whose telephone number is (571)270-3499. The examiner can normally be reached on M-F 9 AM to 7:30 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PAUL W DICKINSON/Primary Examiner, Art Unit 1618 July 22, 2026
Read full office action

Prosecution Timeline

Show 2 earlier events
Mar 24, 2025
Response after Non-Final Action
Oct 22, 2025
Non-Final Rejection mailed — §112
Jan 17, 2026
Response after Non-Final Action
Jan 17, 2026
Response Filed
May 18, 2026
Final Rejection mailed — §112
Jun 26, 2026
Request for Continued Examination
Jun 29, 2026
Response after Non-Final Action
Jul 27, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12673926
NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING
5y 1m to grant Granted Jul 07, 2026
Patent 12649001
COMPLEXES FOR DELIVERY OF ANTIGENIC PEPTIDES
3y 2m to grant Granted Jun 09, 2026
Patent 12642867
CONJUGATES COMPRISING OCULAR ANGIOGENESIS GROWTH FACTOR APTAMERS AND USES THEREOF IN THE DETECTION AND TREATMENT OF OPHTHALMOLOGICAL ANGIOGENESIS INDICATIONS
6y 9m to grant Granted Jun 02, 2026
Patent 12642875
LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF
5y 10m to grant Granted Jun 02, 2026
Patent 12636384
NANOEMULSION WITH PORPHYRIN SHELL
4y 6m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
63%
Grant Probability
73%
With Interview (+9.9%)
3y 3m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1039 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month